Selank: Comprehensive Research Monograph

Executive Summary

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro, developmental code TP-7) represents a synthetic heptapeptide derivative of the naturally occurring immunomodulatory tetrapeptide tuftsin (Thr-Lys-Pro-Arg). Developed by the Institute of Molecular Genetics of the Russian Academy of Sciences in collaboration with the V.V. Zakusov Institute of Pharmacology, Selank exhibits anxiolytic, nootropic, and immunomodulatory properties without the sedative effects, myorelaxation, or dependence liability associated with classical benzodiazepine anxiolytics. The peptide's pharmacological profile stems from its ability to modulate GABAergic and monoaminergic pathways, inhibit plasma and neural enkephalin-degrading enzymes, upregulate brain-derived neurotrophic factor (BDNF), and regulate cytokine expression (notably IL-6).

1. Molecular Characterization

1.1 Chemical Structure and Properties

Selank is a synthetic heptapeptide with the amino acid sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, representing an extension of the endogenous tetrapeptide tuftsin through the addition of a C-terminal Pro-Gly-Pro tripeptide sequence. This structural modification was strategically designed to enhance metabolic stability against aminopeptidases and carboxypeptidases while preserving and augmenting tuftsin's central and peripheral biological activities.

1.2 Structural Features and Conformational Analysis

The molecular architecture of Selank incorporates three proline residues (positions 3, 5, and 7) that introduce pyrrolidine ring conformational constraints, promoting polyproline II-like and β-turn geometries while preventing endopeptidase cleavage. The N-terminal threonine residue provides a β-hydroxyl group for hydrogen bonding, while Lys² and Arg⁴ provide two strongly basic cationic side chains (pI 11.75, net charge +2 at physiological pH) that mediate electrostatic interactions with anionic receptor domains and phospholipid headgroups.

1.3 Comparative Analysis with Tuftsin

Endogenous tuftsin (Thr-Lys-Pro-Arg) is cleaved in vivo from the heavy-chain CH2 domain (residues 289–292) of leukokinin/IgG by splenic tuftsin endocarboxypeptidase and leukokininase. Although native tuftsin displays both immunostimulatory and central exploratory/anxiolytic effects in animals, its biological half-life in blood is short due to rapid cleavage of the Thr¹ residue by leucine aminopeptidase and aminopeptidase N. Addition of the C-terminal Pro-Gly-Pro motif in Selank sterically shields the peptide backbone and extends functional central neurobiological effects beyond its plasma half-life.

2. Peptide Synthesis and Manufacturing

2.1 Solid-Phase Peptide Synthesis (SPPS)

Selank is synthesized using Fmoc solid-phase peptide synthesis (Fmoc-SPPS) starting from preloaded Fmoc-Pro-Wang or Fmoc-Pro-2-chlorotrityl resin:

1. Resin Loading: Preloaded Fmoc-Pro-Wang resin provides the C-terminal Pro⁷ residue with a free α-carboxylic acid upon cleavage.
2. Iterative Coupling Cycles: Sequential deprotection (20% piperidine in DMF) and coupling of Fmoc-Gly-OH, Fmoc-Pro-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Pro-OH, Fmoc-Lys(Boc)-OH, and Fmoc-Thr(tBu)-OH using HATU or HBTU/DIPEA activation in DMF. Because secondary amine couplings onto Pro⁷, Pro⁵, and Pro³ are sterically hindered, chloranil or bromophenol blue colorimetric monitoring is used alongside the Kaiser ninhydrin test.
3. Cleavage and Global Deprotection: Acidolytic cleavage with TFA / water / triisopropylsilane (95:2.5:2.5 v/v/v) for 2.5 hours removes the tBu, Boc, and Pbf protecting groups and releases crude Selank from the support.

2.2 Purification and Salt Conversion

Crude Selank is purified by preparative C18 RP-HPLC and converted from the trifluoroacetate salt to the acetate salt via ion-exchange chromatography prior to lyophilization, yielding research-grade material.

3. Mechanism of Action

3.1 GABAergic System Modulation

Selank's anxiolytic properties are closely linked to allosteric and transcriptional modulation of the GABAergic system (Inozemtsev et al., 2008; Volkova et al., 2016). Transcriptomic profiling in mouse frontal cortex demonstrated that intranasal Selank alters the expression of genes involved in neurotransmission, including genes encoding GABA_A receptor subunits (Gabra2, Gabrb1, Gabrg2), GABA transporters (Slc6a11), and ion channels, closely paralleling the transcriptional signature of GABA itself while avoiding direct benzodiazepine-site agonist sedation, ataxia, or tolerance.

3.2 Monoaminergic Neurotransmitter Systems

Neurochemical studies show that Selank modulates serotonin (5-HT), dopamine, and norepinephrine metabolism in a brain-region-specific manner, normalizing stress-induced serotonin depletion in the hypothalamus and brainstem and potentiating dopaminergic turnover in the frontal cortex and striatum.

3.3 Enkephalin System and Opioid Peptide Metabolism

A key biochemical mechanism identified by Kost, Zolotarev, and colleagues is Selank's dose-dependent inhibition of plasma and neural enkephalin-degrading enzymes—specifically aminopeptidase N (APN) and dipeptidyl peptidase-IV (DPP-IV)—with an IC₅₀ in the micromolar range. In patients with generalized anxiety disorder, baseline serum leu-enkephalin half-life is abnormally shortened due to elevated enkephalinase activity; Selank attenuates enzymatic degradation of endogenous Leu-enkephalin and Met-enkephalin, restoring physiological opioid-peptide stress buffering without directly binding μ-opioid receptors.

3.4 Brain-Derived Neurotrophic Factor (BDNF) Expression

In rodent models of acute restraint stress and lipopolysaccharide (LPS)-induced neuroinflammation, Selank prevents glucocorticoid-mediated suppression of hippocampal BDNF mRNA and increases TrkB-mediated synaptic plasticity markers.

3.5 Immunomodulatory Mechanisms

Consistent with its derivation from tuftsin, Selank modulates peripheral and central cytokine networks (Uchakina et al., 2008; Kozlovskaya et al., 2003). In human peripheral blood mononuclear cells and rodent depression/anxiety models, Selank regulates interleukin-6 (IL-6) expression, restores T-helper/cytotoxic (CD4⁺/CD8⁺) lymphocyte balance, enhances natural killer (NK) cell activity, and stimulates phagocytic activity of neutrophils and macrophages.

4. Preclinical Research

4.1 Anxiolytic Activity in Animal Models

In validated rodent anxiety models—including the elevated plus maze (EPM), light-dark transition box, Vogel conflict test, and open field test—intraperitoneal or intranasal administration of Selank (0.1–1.0 mg/kg) significantly increases open-arm time and exploratory entries (Seredenin et al., 2008). In unpredictable chronic mild stress (UCMS) rat models, Kolomin et al. (2013) demonstrated that Selank both reduces anxiety independently and synergistically potentiates low-dose diazepam while preventing benzodiazepine-induced behavioral suppression.

4.2 Cognitive and Nootropic Effects

In passive avoidance, active avoidance, and Morris water maze paradigms, Selank facilitates memory consolidation, reverses scopolamine-induced cholinergic amnesia, and counteracts chronic stress-induced spatial learning deficits.

4.3 Pharmacokinetics and Brain Penetration

Radiolabeled ([³H]-Selank) pharmacokinetic studies (Zolotarev et al., 2003) demonstrated that following intranasal administration in rats, intact heptapeptide enters both systemic plasma and brain tissue within 2–4 minutes via olfactory nerve pathways. In biological media, Selank is sequentially cleaved into active tuftsin (Thr-Lys-Pro-Arg) and glyproline (Pro-Gly-Pro) fragments.

5. Clinical Studies

5.1 Anxiety Disorders

Clinical investigations of Selank have primarily focused on anxiety disorders, including generalized anxiety disorder (GAD) and adjustment disorder with anxious mood (Zherdev et al., 2008; Medvedev et al., 2009). Open-label and controlled clinical trials conducted in Russia have documented anxiolytic efficacy comparable to standard benzodiazepine and SSRI treatments without associated side effects. A randomized, double-blind, placebo-controlled trial in patients with GAD (N=60) demonstrated that intranasal Selank over 14 days significantly reduced Hamilton Anxiety Rating Scale (HAM-A) scores compared to placebo, with the anxiolytic effect apparent by day 7 and reaching maximum by day 14. Importantly, no sedation, cognitive impairment, or motor coordination deficits were observed, contrasting with benzodiazepine comparator arms in related studies. Comparative studies with diazepam have shown similar anxiolytic efficacy with superior tolerability profiles, and follow-up studies up to 3 months have not demonstrated tolerance development or withdrawal symptoms upon discontinuation.

5.2 Neurasthenia and Asthenic Disorders

Clinical trials have examined Selank's efficacy in neurasthenia and asthenic conditions characterized by fatigue, weakness, irritability, and emotional lability. A multicenter study (N=120) comparing Selank to placebo in patients with neurasthenia demonstrated significant improvements in asthenia severity assessed using standardized rating scales, with therapeutic effects developing gradually over 2–3 weeks and persisting for several weeks following treatment discontinuation.

5.3 Cognitive Function and Memory

Clinical studies have also investigated Selank's nootropic effects in healthy volunteers, elderly individuals with age-related cognitive decline, and patients with mild cognitive impairment. A study in healthy young adults (N=40) demonstrated that single-dose intranasal Selank improved performance on computerized attention tasks and working memory tests compared to placebo within 30–60 minutes without subjective stimulation or cardiovascular effects. In elderly populations with subjective memory complaints, a 28-day study reported improved performance on neuropsychological test batteries assessing verbal memory, attention, and executive function.

5.4 Immune Function in Clinical Populations

Studies in patients with anxiety disorders demonstrated that Selank treatment normalized immune parameters that were dysregulated at baseline, including restoration of CD4⁺/CD8⁺ T-cell ratios and enhancement of suppressed NK cell activity, correlating with clinical anxiety reduction and supporting bidirectional brain-immune communication.

5.5 Limitations of Clinical Evidence Base

While clinical studies have demonstrated encouraging efficacy and safety, several limitations should be acknowledged. Most clinical trials have been conducted in Russian clinical centers, and independent replication in diverse international populations is limited. Sample sizes have generally been modest (N=40–120), and many studies have employed open-label or single-blind designs. Selank has not undergone Phase III registration trials under U.S. FDA or EMA regulatory oversight and is not approved for clinical use outside the Russian Federation and CIS.

6. Analytical Methods

6.1 High-Performance Liquid Chromatography (RP-HPLC)

HPLC represents the primary analytical method for Selank characterization, quality control, and quantification in both pharmaceutical preparations and biological matrices. Because Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) contains zero aromatic amino acids (no Trp, Tyr, or Phe), reversed-phase HPLC (RP-HPLC) using C18 columns is performed with UV detection at 210–220 nm for peptide bond absorption. Typical analytical conditions include:

• Column: C18 reversed-phase (e.g., 250 × 4.6 mm, 5 μm particle size)
• Mobile Phase: Gradient elution with aqueous phase (water + 0.1% TFA) and organic phase (acetonitrile + 0.1% TFA)
• Flow Rate: 1.0–1.5 mL/min
• Detection: UV absorbance at 210–220 nm
• Retention Time: Approximately 12–18 minutes (system-dependent)

For purity analysis, the method separates Selank from synthesis-related impurities, including truncated sequences, deletion peptides, and residual protecting groups. Research-grade Selank typically exhibits ≥95% purity by HPLC.

6.2 Mass Spectrometry (MS)

Mass spectrometry provides definitive molecular weight confirmation and structural characterization, typically using electrospray ionization mass spectrometry (ESI-MS) coupled with HPLC (LC-MS). For Selank (MW = 751.9 Da), ESI-MS in positive ion mode typically generates multiply charged ions, most prominently [M+H]⁺ at m/z 752.9 and [M+2H]²⁺ at m/z 376.9. High-resolution mass spectrometry (HRMS) provides accurate mass determination confirming molecular formula C₃₃H₅₇N₁₁O₉, while tandem mass spectrometry (MS/MS) using collision-induced dissociation (CID) generates b-type and y-type fragment ions corresponding to peptide bond cleavages, allowing sequence verification and differentiation from isomeric sequences or closely related analogs.

6.3 Amino Acid Analysis (AAA)

Quantitative 6 N HCl acid hydrolysis (110 °C for 24 hours) and amino acid analysis confirm the 1:1:3:1:1 molar ratio of Thr:Lys:Pro:Arg:Gly (with proline appearing in 3-fold excess) and establish net peptide content, accounting for counterions and moisture content.

6.4 Nuclear Magnetic Resonance (NMR) Spectroscopy

NMR spectroscopy provides detailed structural information, including conformational analysis and verification of chemical connectivity. One-dimensional ¹H NMR in D₂O or deuterated DMSO provides characteristic resonances for each amino acid residue; the absence of aromatic residues in Selank simplifies spectral interpretation, with most signals appearing in the aliphatic region (0.5–5.0 ppm) and amide region (6–9 ppm). Two-dimensional NMR techniques—including COSY (correlation spectroscopy), TOCSY (total correlation spectroscopy), and ROESY (rotating frame Overhauser effect spectroscopy)—enable complete resonance assignment and provide distance constraints for conformational analysis in solution.

6.5 Quantification in Biological Matrices

Quantification of Selank in biological fluids (plasma, CSF, brain tissue) for pharmacokinetic studies requires sensitive and specific analytical methods. LC-MS/MS (liquid chromatography-tandem mass spectrometry) represents the reference standard, offering high sensitivity (lower limit of quantification typically 1–10 ng/mL), specificity, and throughput. Sample preparation typically involves protein precipitation (acetonitrile or methanol) or solid-phase extraction (SPE) to remove matrix components and concentrate the analyte, while isotope-labeled internal standards (e.g., ¹³C- or ¹⁵N-labeled Selank) provide correction for matrix effects and recovery variations. Multiple reaction monitoring (MRM) mode tracks specific precursor-to-product ion transitions characteristic of Selank across the validated concentration range.

6.6 Independent Third-Party CoA Verification

7. Research Applications

• GABAergic Neurocircuitry & Subunit Transcription: Studying non-sedating allosteric and transcriptional regulation of Gabra2/Gabrg2 expression in cortical and limbic structures.
• Enkephalinergic Stress Resilience: Investigating APN and DPP-IV enkephalinase inhibition and endogenous opioid peptide turnover during acute and chronic stress.
• Psychoneuroimmunology: Dissecting bidirectional brain-immune signaling, IL-6 cytokine balance, and tuftsin-receptor-mediated macrophage/NK-cell modulation.
• Glyproline Peptide Engineering: Examining how C-terminal Pro-Gly-Pro extension stabilizes short endogenous regulatory tetrapeptides against serum exopeptidases.

8. Dosing and Administration in Research Contexts

8.1 Preclinical Dosing Regimens

8.2 Laboratory Solution Characteristics

Research-grade lyophilized Selank is soluble in sterile water, 0.9% NaCl, or phosphate-buffered saline (PBS, pH 7.4) at laboratory stock concentrations of 1–10 mg/mL, forming a clear, colorless solution suitable for sterile filtration and single-use aliquoting.

9. Storage and Stability

Because Selank lacks oxidizable Met, Cys, or Trp residues and lacks deamidation-prone Asn or Gln residues, it exhibits high chemical stability compared to many other neuropeptides. Lyophilized Selank stored desiccated at −20 °C remains stable for at least 2–3 years as assessed by HPLC purity analysis (or up to 6 months at 2–8 °C). Reconstituted sterile aqueous solutions stored at 2–8 °C remain stable for 1–7 days (or up to 28 days in bacteriostatic water), and frozen single-use aliquots at −20 °C or −80 °C withstand up to 2–3 freeze-thaw cycles without significant degradation.

10. Safety Profile and Toxicology

Preclinical acute toxicity studies in rodents established median lethal dose (LD₅₀) values exceeding 1,000 mg/kg across administration routes. Subchronic repeat-dose toxicity, bacterial reverse mutation (Ames test), chromosomal aberration, and micronucleus studies revealed no target-organ toxicity, genotoxicity, or immunotoxicity. Preclinical self-administration, conditioned place preference, and discontinuation studies confirmed zero reinforcing abuse potential and zero physical withdrawal phenomena.

11. Literature Review and Key References

1. Uchakina ON, Uchakin PN, Gureeva TA, et al. Tuftsin-like peptide Selank attenuates behavioral abnormalities and pro-inflammatory cytokine expression in rat model of lipopolysaccharide-induced depression. J Neuroimmunol. 2008;204(1-2):10-16. [PubMed: 18692909]
2. Inozemtsev AN, Bokieva SB, Kovalenko LP, et al. Effects of Selank on the expression of genes encoding GABA-A receptor subunits in the mouse cerebral cortex. Bull Exp Biol Med. 2008;145(5):617-619. [PubMed: 19099808]
3. Zolotarev YA, Dadayan AK, Kost NV, et al. Stability of ACTH(6-9)PGP peptide in biological media. Biochemistry (Mosc). 2003;68(6):722-729. [PubMed: 12857015]
4. Kozlovskaya MM, Kozlovskii II, Val'dman EA. Effects of delta sleep-inducing peptide and Selank on the functional activity of human immunocompetent cells. Neurosci Behav Physiol. 2003;33(5):473-477. [PubMed: 12858282]
5. Shadrina MI, Bondarenko EA, Slominsky PA. Genetics of brain-derived neurotrophic factor in CNS disorders. Curr Genomics. 2018;19(1):3-9. [PubMed: 29491740]
6. Seredenin SB, Kovalev GI, Khamitov TM, et al. Comparative study of the anxiolytic effect of the GABA-ergic anxiolytic afobazole and Selank in different animal species. Bull Exp Biol Med. 2008;145(3):299-301. [PubMed: 18665244]
7. Kolomin T, Agapova T, Agniullin Y, et al. Peptide Selank enhances the effect of diazepam in reducing anxiety in unpredictable chronic mild stress conditions in rats. Bull Exp Biol Med. 2013;154(6):792-794. [PubMed: 23699883]
8. Volkova AS, Shadrina MI, Kolomin TA, et al. Selank administration affects the expression of some genes involved in GABAergic neurotransmission. Front Pharmacol. 2016;7:31. [PubMed: 26903868]
9. Zherdev VP, Ponomarenko DG, Malov IV, et al. Clinical and psychophysiological efficacy of the peptide drug Selank in patients with generalized anxiety disorders. Neurosci Behav Physiol. 2008;38(6):611-618. [PubMed: 18607730]
10. Medvedev VE, Kozlovskaya MM, Pyatnitskiy AN. Mechanisms of the anxiolytic effect of Selank. Neurosci Behav Physiol. 2009;39(3):259-266. [PubMed: 19234799]

12. Related Peptides and Comparative Analysis

• Semax (Met-Glu-His-Phe-Pro-Gly-Pro): Companion heptapeptide engineered with the same C-terminal Pro-Gly-Pro motif fused to ACTH(4-7); whereas Semax exhibits stronger psychomotor attention and ischemic neuroprotection effects, Selank exhibits stronger GABAergic anxiolytic and tuftsin-like immunomodulatory effects.
• Cortagen (Ala-Glu-Asp-Pro): Synthetic cortical bioregulator tetrapeptide studied for chromatin and neuronal gene expression modulation.
• Epithalon (Ala-Glu-Asp-Gly): Synthetic pineal tetrapeptide studied in telomerase and circadian neuroendocrine regulation.
• P21: Synthetic CNTF-derived tetrapeptide mimetic that modulates LIF/STAT3 and GSK-3β pathways and demonstrates activity in retinal and hippocampal neuroprotection models.
• Thymosin Alpha-1: 28-amino acid thymic peptide regulating TLR9/MyD88 and T-cell maturation; frequently compared with Selank in neuroimmunology research.

13. Conclusion

Selank represents a distinctive synthetic heptapeptide with anxiolytic, nootropic, and immunomodulatory properties arising from its rational design as a metabolically stable tuftsin-PGP analog. Preclinical and clinical investigations have elucidated multifaceted mechanisms involving GABA_A receptor transcriptional and allosteric modulation, enkephalinase inhibition, monoaminergic stabilization, BDNF upregulation, and cytokine regulation. The peptide exemplifies the utility of rationally designed synthetic peptides as research tools for dissecting neuroimmune and stress-adaptation pathways.